about
Bypassing agent prophylaxis in people with hemophilia A or B with inhibitorsTreatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgeryTreatment for preventing bleeding in people with congenital bleeding disorders undergoing surgeryHuman von Willebrand factor/factor VIII concentrates in the management of pediatric patients with von Willebrand disease/hemophilia AImportance of immune response genes in hemophilia APresent and future challanges in the treatment of haemophilia: a clinician's perspectiveThe safety of pharmacologic options for the treatment of persons with hemophilia.Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IXCurrent and evolving features in the clinical management of haemophiliaPrinciples of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in ItalyInhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression.Advanced therapies for the treatment of hemophilia: future perspectives.The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.Factor VIII inhibitors: a 50-year perspective.Past, present and future of hemophilia: a narrative review.The modern treatment of haemophilia: a narrative reviewFactor VIII therapy for hemophilia A: current and future issues.The role of Rixubis™ in the treatment of hemophilia B.Current management of the hemophilic child: a demanding interlocutor. Quality of life and adequate cost-efficacy analysis.Strategies for reducing inhibitor formation in severe haemophilia.The role of previously untreated patient studies in understanding the development of FVIII inhibitors.Inhibitors in haemophilia A: a perspective on clotting factor products as a potential contributing factor.The Development of FVIII Inhibitors in Relation to IL10 Gene Polymorphism in Hemophilia A Egyptian Pediatric Patients.Tailoring hemostatic therapies to lower inhibitor development in previously untreated patients with severe hemophilia A.First molecular analysis of F8 gene in algeria: identification of two novel mutations.Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.Prompt immune tolerance induction at inhibitor diagnosis regardless of titre may increase overall success in haemophilia A complicated by inhibitors: experience of two U.S. centres.Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better.Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors.Treatment for hemophilia: recombinant versus plasma-derived coagulation factors - controversy and debate forever? An ethical medical challenge?Answering relevant research questions via careful observation of clinical practice: a fresh look at the old way forward.Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII (GreenGene F™) in Korean Patients with Hemophilia A: Data from a Post-marketing Surveillance Study.Exposure to factor VIII and prediction of inhibitor development: exposure days vs. danger days, or both?Lonoctocog alfa (rVIII-SingleChain) for the treatment of haemophilia A.Population-specific design of de-immunized protein biotherapeutics.
P2860
Q24187021-1E6CB3F4-52B3-4C6C-A627-AAE67E6A5481Q24188177-629EB94D-F537-458F-BAF8-3E827E758E2EQ24202459-AD1C066D-65FB-4B5C-B59B-589E112E6486Q26738507-D5BEF520-5BD3-4A3F-9D28-632C5A916589Q27025467-B8FB3FB3-3656-49E1-8C45-C6B002AF6B8DQ27026137-238C2282-95DD-4C3B-B0F0-D242FC2F68B5Q30249200-53D88C2D-73F6-466B-BF1C-D611D9D6F348Q33608230-F51FC795-0429-4A9A-A892-91F41FB7033EQ33708976-95E9829A-4308-47EC-B284-5518B38DAB89Q34416394-B976EF51-FA44-4BF4-900A-FA39406BB370Q34784564-FCB2CDE9-EA02-4C7B-9951-B657DA35EFF4Q36552555-E9A49AB5-CB35-4496-8227-AFD839A16036Q36628311-C14AB9A2-1705-4B9D-A8BA-DBE54C02A65DQ37876956-6EB59F7D-15BF-479B-BDA0-FBCC117C46C4Q38007018-1B09AFBE-D359-472D-87F2-986C9323CE1EQ38025882-8A80C5BC-22FD-4EE6-BA88-C1BC0C32610EQ38203350-1447FD33-15C1-495F-9D8C-4C5D1D5AD707Q38210808-5F57C248-9212-4770-B6DE-52808E17CAF3Q38227605-5631593D-0DBB-4AFD-9CF0-096331DB29ACQ38308222-5F7CE590-10C9-417E-95CA-448B2CC6D947Q38575475-23E4D46E-D8EA-4104-B5B4-F47C466E8B33Q38722283-E72C25F1-E21E-46AB-8C7F-33A5E340E25CQ38748723-8D6C54A5-B3BC-4A0A-BD89-29293929A6CFQ38828174-B7E2502C-F171-4661-927A-3125DEB6768BQ38856096-350ECF9F-3BA0-4B04-9B7B-13E57D3662BDQ38944642-100825A4-29D0-41F5-9194-EF6B4BD26D04Q41592459-EE0FB37D-8913-414B-8226-3F90DA329D77Q42408107-C5ED807B-FA59-4001-AC3D-BD99C775329DQ42692841-907DBE28-793D-4391-B27D-CA2010A6DF0DQ45856894-B2BF41E3-855A-44A4-8ABE-232D3E2EB04EQ45867907-9160D8EF-7E1D-4EEB-A59E-521A8511CC5AQ45875555-CC140E3C-01AB-4F51-9B5A-0660EAA8F99CQ45880913-C70BB286-F76B-4747-9F3B-449047FDE6F3Q50139622-BF627471-24B4-4F21-A4EC-A75822048500Q50421163-1E9EC47C-8E1D-4F2D-8853-315C4F6FA2CD
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Inhibitor development: patient-determined risk factors.
@en
Inhibitor development: patient-determined risk factors.
@nl
type
label
Inhibitor development: patient-determined risk factors.
@en
Inhibitor development: patient-determined risk factors.
@nl
prefLabel
Inhibitor development: patient-determined risk factors.
@en
Inhibitor development: patient-determined risk factors.
@nl
P1433
P1476
Inhibitor development: patient-determined risk factors.
@en
P2093
J Astermark
P356
10.1111/J.1365-2516.2008.01923.X
P577
2009-02-27T00:00:00Z